ff FY18 Guidance: The Management expects sales (including gZetia) to grow by 6% YoY, while pegging EBITDA margin and gross margin at 21-22% and 68%, respectively. R&D; spend is pegged at 11-13% of sales. GNP plans to launch Ceylon Pharma's product (SalmaxgAdvair/...